MX2022010407A - Forma de dosis oral de rápida dispersión de rimegepant. - Google Patents
Forma de dosis oral de rápida dispersión de rimegepant.Info
- Publication number
- MX2022010407A MX2022010407A MX2022010407A MX2022010407A MX2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A MX 2022010407 A MX2022010407 A MX 2022010407A
- Authority
- MX
- Mexico
- Prior art keywords
- rimegepant
- dosage form
- dispersing dosage
- fast
- oral fast
- Prior art date
Links
- KRNAOFGYEFKHPB-ANJVHQHFSA-N [(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate Chemical compound C1([C@H]2[C@@H](C3=CC=CN=C3[C@H](OC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)N)=CC=CC(F)=C1F KRNAOFGYEFKHPB-ANJVHQHFSA-N 0.000 title abstract 4
- 239000002552 dosage form Substances 0.000 title abstract 4
- 229950004372 rimegepant Drugs 0.000 title abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona una forma de dosis de rápida dispersión para administración oral, en donde la forma de dosis de rápida dispersión incluye un rimegepant. También se proporciona un 5 método para administrar rimegepant a un sujeto, en donde el método incluye administrar por vía oral al sujeto una composición que incluye una forma de dosis de rápida dispersión que incluye rimegepant.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982456P | 2020-02-27 | 2020-02-27 | |
PCT/US2021/019825 WO2021173936A1 (en) | 2020-02-27 | 2021-02-26 | Oral fast-dispersing dosage form of rimegepant |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010407A true MX2022010407A (es) | 2022-11-07 |
Family
ID=77492027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010407A MX2022010407A (es) | 2020-02-27 | 2021-02-26 | Forma de dosis oral de rápida dispersión de rimegepant. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230108049A1 (es) |
EP (1) | EP4110337A4 (es) |
JP (1) | JP2023515535A (es) |
KR (1) | KR20220146535A (es) |
CN (1) | CN115335051A (es) |
AU (1) | AU2021227937A1 (es) |
BR (1) | BR112022016790A2 (es) |
CA (1) | CA3172358A1 (es) |
IL (1) | IL295926A (es) |
MX (1) | MX2022010407A (es) |
WO (1) | WO2021173936A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230015324A (ko) * | 2020-03-29 | 2023-01-31 | 바이오헤이븐 파마슈티컬 아일랜드 디에이씨 | 편두통의 예방적 치료 |
WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9026998D0 (en) * | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
CN110636834A (zh) * | 2017-02-15 | 2019-12-31 | 分子浸剂有限公司 | 制剂 |
BR112020019396A2 (pt) * | 2018-03-25 | 2021-01-05 | Biohaven Pharmaceutical Holding Company Ltd. | Rimegepant para distúrbios relacionados a cgrt |
-
2021
- 2021-02-26 BR BR112022016790A patent/BR112022016790A2/pt not_active Application Discontinuation
- 2021-02-26 IL IL295926A patent/IL295926A/en unknown
- 2021-02-26 CA CA3172358A patent/CA3172358A1/en active Pending
- 2021-02-26 EP EP21761490.8A patent/EP4110337A4/en active Pending
- 2021-02-26 KR KR1020227032667A patent/KR20220146535A/ko unknown
- 2021-02-26 AU AU2021227937A patent/AU2021227937A1/en active Pending
- 2021-02-26 US US17/801,295 patent/US20230108049A1/en not_active Abandoned
- 2021-02-26 JP JP2022550949A patent/JP2023515535A/ja active Pending
- 2021-02-26 WO PCT/US2021/019825 patent/WO2021173936A1/en unknown
- 2021-02-26 MX MX2022010407A patent/MX2022010407A/es unknown
- 2021-02-26 CN CN202180016554.9A patent/CN115335051A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115335051A (zh) | 2022-11-11 |
JP2023515535A (ja) | 2023-04-13 |
BR112022016790A2 (pt) | 2022-11-08 |
EP4110337A4 (en) | 2024-03-20 |
EP4110337A1 (en) | 2023-01-04 |
WO2021173936A1 (en) | 2021-09-02 |
AU2021227937A1 (en) | 2022-09-08 |
KR20220146535A (ko) | 2022-11-01 |
CA3172358A1 (en) | 2021-09-02 |
US20230108049A1 (en) | 2023-04-06 |
IL295926A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010407A (es) | Forma de dosis oral de rápida dispersión de rimegepant. | |
ZA201608614B (en) | Solid oral pharmaceutical compositions for isoxazoline compounds | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
SI1746980T1 (sl) | Farmacevtska dozirna oblika ki obsega pelete kot tudi postopek za njeno pripravo | |
NZ597488A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
MX2021015827A (es) | Antagonista de neurokinin -1. | |
MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
BR112018068784A2 (pt) | método para o tratamento de leucemia | |
MX2023003758A (es) | Formulaciones farmaceuticas. | |
MX2022011651A (es) | Composicion farmaceutica para tratamiento de diabetes. | |
MX2022016341A (es) | Formas farmaceuticas de maleato de acalabrutinib. | |
MX2022013884A (es) | Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia. | |
TW201613606A (en) | Therapeutic drug for chronic renal failure | |
MX2022000426A (es) | Telmisartan para el tratamiento de la hipertension en perros. | |
MX2023013983A (es) | Metodo de tratamiento del temblor esencial. | |
MX2024000084A (es) | Compuesto de tiazololactama dimetil sustituido y uso de este. | |
JP1770167S (ja) | 投薬用鼻腔挿入器 | |
UA95834U (uk) | Спосіб лікування гострого ішемічного інсульту | |
UA115803U (xx) | Спосіб лікування вертеброгенних радикулопатій | |
UA74059U (ru) | Способ комплексного лечения эхинококковой болезни |